Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

The treatment patterns and adverse reactions of bevacizumab in the Chinese population in the real world.

Yang Song, Liping Fang, Fang Su et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23267

e23267 Background: Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor (VEGF), which can be used to treat many types of canc...

Progressive NK cell dysfunction and ILC imbalance as drivers of immune evasion in multiple myeloma.

Antonio Solimando, Maria Teresa Bilotta, Vanessa Desantis et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19557

e19557 Background: Innate lymphoid cells (ILCs), including Natural killer (NK), exhibit distinct phenotypic and functional changes during multiple myeloma...

Change in T2-weighted signal intensity, change in tumor volume, and exposure-response analysis in the RINGSIDE phase 2 study of varegacestat in patients with desmoid tumors.

Mrinal M. Gounder, Bernd Kasper, Rashmi Chugh et al. Jun 01, 2025 pp. 11557-11557 10.1200/jco.2025.43.16_suppl.11557

11557 Background: T2-weighted signal intensity (T2W) and tumor volume (TV) on MRI may be more sensitive than RECIST for assessing treatment effect in desm...

The hidden toll: Defining impacts of home call on oncology fellows.

Erica Andres, Savannah Liddell, Rosalyn Marar et al. Jun 01, 2025 pp. 9021-9021 10.1200/jco.2025.43.16_suppl.9021

9021 Background: Home call is an expected trainee responsibility in many hematology-oncology (HO) training programs although the specific duties and frequ...

Opinions of real-world clinicians on endocrine resistance in HR+/HER2- mBC: Results from the RETRACT survey of US oncologists.

William John Gradishar, Erika P. Hamilton, Reshma L. Mahtani et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13064

e13064 Background: Endocrine therapy (ET) is the treatment of choice in patients with metastatic breast cancer (mBC), but the benefit is limited by the in...

Allogeneic hematopoietic cell transplantation for acute leukemia patients not in complete remission.

Shlomo Elias, Samantha Brown, Ogechukwu Egini et al. Jun 01, 2025 pp. 6553-6553 10.1200/jco.2025.43.16_suppl.6553

6553 Background: Current guidelines support allogeneic hematopoietic cell transplantation (allo-HCT) in patients with acute leukemia who achieve complete...

From food deserts to clinical trial deserts: Challenges in access to breast cancer trials.

Rachel Ann Sachs, Larissa Pamen, Shruthi Reddy Perati et al. Jun 01, 2025 pp. 1525-1525 10.1200/jco.2025.43.16_suppl.1525

1525 Background: Patients who live in food deserts have high mortality rates from breast cancer and stand to benefit from participating in research studie...

Maintaining momentum in cancer health equity: Examining Native Hawaiian and Pacific Islander US cancer mortality trends (1999-2024) and mechanisms for enhancing representation in oncology clinical trials.

Kade Shippy, Pierre Theodore, Vanessa Di Felice et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23327

e23327 Background: Native Hawaiian and Pacific Islanders (NHPI) face higher cancer mortality rates compared to White people, with a 75% increased likeliho...

Pertuzumab plus trastuzumab (P+T) in patients (pts) with bladder (BC) and ovarian cancer (OC) with <i>ERBB2/3</i> alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

John K. Chan, Michael Rothe, Pam K. Mangat et al. Jun 01, 2025 pp. 3126-3126 10.1200/jco.2025.43.16_suppl.3126

3126 Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers wit...

A phase II study of the interleukin-6 (IL-6) receptor blocking antibody sarilumab (Sari) in combination with ipilimumab (Ipi), nivolumab (Nivo) and relatlimab (Rela) in patients with unresectable stage III or stage IV melanoma.

Janice M. Mehnert, Inderjit Mehmi, Judith D. Goldberg et al. Jun 01, 2025 pp. 9510-9510 10.1200/jco.2025.43.16_suppl.9510

9510 Background: Combination immune checkpoint inhibitor regimens, especially those utilizing anti-CTLA-4 blockade, demons...

The effect of patient self-reported confidence on psychosocial outcomes in the context of lymphoma and chronic lymphocytic leukaemia.

Steve Kalloger, Amanda Watson, Shawn Sajkowski et al. Jun 01, 2025 pp. 7074-7074 10.1200/jco.2025.43.16_suppl.7074

7074 Background: Adverse psycho-social outcomes (APSO’s) are common side effects often underreported which have great impact on the wellbeing of patients...

Overall survival with fruquintinib versus placebo after adjusting for subsequent anticancer therapy in patients with refractory metastatic colorectal cancer in the FRESCO-2 study.

Sara Lonardi, Arvind Dasari, Josep Tabernero et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15568

e15568 Background: Fruquintinib is a highly selective, oral inhibitor of all 3 vascular endothelial growth factor receptors (VEGFRs -1, -2, and -3) that i...

Hyperlipidemia as adverse event of lorlatinib, a multicenter cohort study.

Fei Xu, Yuan Cheng, Yan Wang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e24040

e24040 Background: Lorlatinib, a third-generation tyrosine kinase inhibitor targeting ALK mutations, has shown superior efficacy in patients with advanced...

A novel device to simultaneously collect standard core biopsies and dislodged cancer cells from solid tumors for molecular testing.

Saloni Walia, Pamela Ward Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13898

e13898 Background: The molecular profiling of breast cancer is becoming an integral component of patient care. Routine pathology lab processing creates ba...

Trends and disparities in diffuse large B-cell lymphoma mortality among older adults in the United States (1999-2020): A CDC WONDER database analysis.

Saad Nasir, Munira Moosajee, Sairah Ahmed Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13734

e13734 Background: Despite treatment advancements, diffuse large B-cell lymphoma (DLBCL) remains a significant public health concern. This study evaluates...

Detection of early-stage colorectal cancer using multiplexed extracellular vesicle proteomic biomarkers.

Todd A. Hembrough, Poorva Mudgal, Zachary Opheim et al. Jun 01, 2025 pp. 3616-3616 10.1200/jco.2025.43.16_suppl.3616

3616 Background: Colorectal cancer (CRC) is very common worldwide, and detection of early-stage cancer is critical for improved survival rates. Advanced a...

Multimodal machine learning predictions of treatment response and survival in advanced pancreatic cancer from the COMPASS trial.

Wei Quan, David Henault, Gun Ho Jang et al. Jun 01, 2025 pp. 4181-4181 10.1200/jco.2025.43.16_suppl.4181

4181 Background: Pancreatic cancer is an aggressive malignancy with limited therapeutic options and a poor prognosis. Curr...

HBV-TCR T cell therapy: Preclinical and clinical insights into specificity, safety and efficacy for treating HBV-related HCC.

Anthony Tanoto Tan, Lu-En Wai, Regina Wong et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14525

e14525 Background: LioCyx-M, an autologous T-cell therapy modified with mRNA encoding HBV-specific TCRs, was developed using a TCR selected from a proprie...

Analysis of readmission rates, length of stay and mortality among bone marrow transplant and CAR-T patients in a rural state.

Kingsley Chinonyerem Nnawuba, Samantha Robinson, Chinemerem MARTLIN Emeasoba et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19021

e19021 Background: Bone marrow transplantation (BMT) and chimeric antigen receptor T-cell (CAR-T) therapy has become an integral treatment modality for se...

AI for evidence-based treatment recommendation in oncology: A blinded evaluation of large language models and agentic workflows.

Guannan Zhai, Merav Bar, Andrew Cowan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13656

e13656 Background: Evidence-based medicine is crucial for clinical decision-making, yet studies suggest that a significant proportion of treatment decisio...

Systemic mastocytosis: A study of trends, survival and second primary malignancies among adults in the United States.

Chiamaka Elsie Nwachukwu, Lingxiao Viviano, Simo Du et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18597

e18597 Background: Systemic mastocytosis is a rare hematologic disorder characterized by the clonal proliferation and accumulation of aberrant mast cells...

Exploring unmet needs in radiation-induced nausea and vomiting after moderately emetogenic treatment.

Sarah Arn Lowry, Andy Kaempf, Jeong Youn Lim et al. Jun 01, 2025 pp. 12124-12124 10.1200/jco.2025.43.16_suppl.12124

12124 Background: Despite their prevalence and clinical significance, interventions to improve radiation-induced nausea and vomiting (RINV) are insufficie...

Proteogenomic characterization of antibody-drug conjugate target expression profiles in transcriptional subtypes of small cell lung cancer.

Edwin Lin, Mitch Singstock, Sanad Alhushki et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20113

e20113 Background: Small cell lung cancer (SCLC) is a highly lethal malignancy, and there is an urgent need for more effective therapies. Antibody-drug co...

Clinical-pathological differences in colorectal cancer: Rectum, left colon, and microsatellite instability—ABDON study.

Bruna Teixeira Marques, Matheus Coimbra Barroso, Henrique Jin Son Kim et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15653

e15653 Background: Colorectal cancer (CRC) is a heterogeneous disease and shows distinct clinical-pathological features based on tumor location and molecu...

Prognostic factors and survival outcome of brain metastases in breast cancer patients: A retrospective analysis.

Sajid Durrani, Ahmed Alanazi, Anas Ali Alghamdi et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14005

e14005 Background: Brain metastasis (BM) is an increasingly complicated issue in breast cancer (BC) patients, occurring in approximately 10% to 30% of cas...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page